Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
July 20, 2026Pamplona/MadridIn recruitmentEarly phase
VVD-133214-01 Phase I clinical trial of RO7589831 in participants with advanced solid tumors.
The primary objective of this trial is to determine whether RO7589831 administered at different doses has effects, whether positive or negative, as well as what happens to RO7589831 once it enters the body and how it acts in the body and on your disease. -
July 20, 2026Pamplona/MadridIn recruitment
T3P1001 Phase I/II, open-label clinical trial of T3P-Y058-739, a genetically modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
The primary objective of the trial is to determine: the best way to safely administer T3P to patients; the side effects of T3P and how they can be managed; and whether T3P can shrink or control cancers. -
July 19, 2026Pamplona/MadridIn recruitment
79635322MMY3002 Randomized phase III clinical trial comparing JNJ-79635322 with teclistamab in patients with relapsed or refractory multiple myeloma after 1 to 3 prior lines of treatment, including an anti-CD38 antibody and lenalidomide (TRIlogy-5).
The objective of this study is to compare the effects of JNJ-79635322 with those of teclistamab. Teclistamab is already used to treat adults with multiple myeloma. -
July 13, 2026Pamplona/MadridIn recruitment
ZL-1310-003 Phase III, randomized, open-label clinical trial of ZL-1310, a DLL3-targeted antibody-drug conjugate (ADC), compared with investigator’s choice of therapy in participants with relapsed small cell lung cancer.
The objective is to study the samples to understand their responses to the study drug and to obtain more information about small cell lung cancer. -
July 9, 2026MadridIn recruitmentEarly phase
300163 Phase I clinical trial of GSK5533524 alone or in combination with other antineoplastic agents in adult participants with selected advanced solid tumors.
The primary objective is to evaluate the safety and tolerability of GSK5533524 as monotherapy in PROC and to select the dose(s) for evaluation in Part 1b. -
July 9, 2026MadridIn recruitmentEarly phase
LCB-1801-001 Phase I study of the NI-1801 antibody targeting mesothelin x CD47, as a single agent and in combination with the anti-PD-1 antibody or with paclitaxel in patients with solid cancers.
The objective of this research is to evaluate whether the study drug NI-1801, as a single agent, in combination with pembrolizumab, in combination with paclitaxel (randomized cohort I), or in combination with pembrolizumab and standard chemotherapy-based treatment with paclitaxel (randomized cohort II), has potential beneficial effects and is safe for patients with these types of cancer. -
July 8, 2026Pamplona/MadridIn recruitmentEarly phase
XL092-002 Dose-escalation and expansion study to evaluate the safety and efficacy of XL092 in combination with immuno-oncology drugs in patients with unresectable advanced or metastatic solid tumors.
The objective of this study is to evaluate potential new cancer treatments for people with tumors similar to yours. The sponsor wants to find out what effects, positive or negative, these treatments have on you and your disease. -
July 2, 2026Pamplona/MadridIn recruitment
CA254-0001 Phase 1/2a, first-in-human, open-label clinical trial of BMS-986517 as monotherapy in adult participants with advanced solid tumors.
This study is designed to help us determine whether the study drug BMS-986517 works to treat advanced solid tumors. Experts are continuing to investigate BMS-986517 to learn about its side effects and efficacy. The study drug has not yet been approved by the Food and Drug Administration (FDA) or other regulatory agencies for the treatment of advanced solid tumors or any other medical condition. -
June 25, 2026Pamplona/MadridIn recruitmentEarly phase
M-2020-371 Clinical trial of MB-CART2019.1 compared with standard of care in participants with relapsed/refractory diffuse large B-cell lymphoma.
The objective of this study is to determine whether an investigational drug called MB-CART2019.1 is more effective than a second standard chemotherapy treatment for your disease. This study will also investigate the safety of MB-CART2019.1 when administered to patients and will determine whether there are any changes in their quality of life. -
June 15, 2026PamplonaIn recruitment
C1071015 A TRIAL FOR PARTICIPANTS WITH MULTIPLE MYELOMA WHO HAVE PARTICIPATED IN PFIZER-SPONSORED CLINICAL TRIALS OF ELRANATAMAB
The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude.